<DOC>
	<DOC>NCT01109121</DOC>
	<brief_summary>This Phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe gout.</brief_summary>
	<brief_title>Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Tranilast</mesh_term>
	<criteria>Male or female, aged 18 to 80 Severe gout, demonstrated by 3 or more gout flares in the previous 12 months, or the presence of at least one gout tophus or gouty arthritis Hyperuricemia with a sUA â‰¥8.0 mg/dL Pregnant or nursing Known hypersensitivity to any of the components of tranilast or allopurinol Known history of xanthinuria or kidney stones Use of an investigational drug within 30 days Presence of, or history of, cancer with the exception of completely excised, nonmetastatic squamous cell and basal cell carcinomas of the skin Subject is planning or likely to require a surgical procedure during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Moderate to severe gout</keyword>
	<keyword>Hyperuricemia</keyword>
</DOC>